bioAffinity Technologies Inc. Warrant
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell… Read more
bioAffinity Technologies Inc. Warrant (BIAFW) - Total Liabilities
Latest total liabilities as of September 2025: $2.64 Million USD
Based on the latest financial reports, bioAffinity Technologies Inc. Warrant (BIAFW) has total liabilities worth $2.64 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
bioAffinity Technologies Inc. Warrant - Total Liabilities Trend (2019–2024)
This chart illustrates how bioAffinity Technologies Inc. Warrant's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
bioAffinity Technologies Inc. Warrant Competitors by Total Liabilities
The table below lists competitors of bioAffinity Technologies Inc. Warrant ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GeoVax Labs Inc
NASDAQ:GOVX
|
USA | $1.82 Million |
|
TV Thunder Public Company Limited
BK:TVT
|
Thailand | ฿38.95 Million |
|
Intersport Polska S.A.
WAR:IPO
|
Poland | zł210.92 Million |
|
Commcenter S.A.
MC:CMM
|
Spain | €25.75 Million |
|
AFP Capital SA
SN:AFPCAPITAL
|
Chile | CL$181.66 Billion |
|
Bubalus Resources Ltd
AU:BUS
|
Australia | AU$122.42K |
|
STORE ELECTRONIC
BE:S4M
|
Germany | €775.00 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down bioAffinity Technologies Inc. Warrant's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how bioAffinity Technologies Inc. Warrant's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for bioAffinity Technologies Inc. Warrant (2019–2024)
The table below shows the annual total liabilities of bioAffinity Technologies Inc. Warrant from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $3.91 Million | +16.20% |
| 2023-12-31 | $3.37 Million | +195.63% |
| 2022-12-31 | $1.14 Million | -93.40% |
| 2021-12-31 | $17.24 Million | +13.31% |
| 2020-12-31 | $15.22 Million | +224.19% |
| 2019-12-31 | $4.69 Million | -- |